NeoGenomics, Inc.

The current price of NEO is $16.51 — it has decreased by 3.73% since the previous close. Data as of Nov 5, 2026.

NEO is down 8.91% over the past week, down 14.53% over the past month and up 56.76% over the past year. The price is above its 200-day moving average of $12.84.

Analysts' average 12-month price target for NEO is $22.50, which implies 36.28% upside from the current price. Individual estimates range from $19.00 to $28.00.

Of the 11 analysts covering NeoGenomics, Inc., 2 rate it a strong buy, 6 rate it a buy and 3 rate it a hold. The overall consensus is bullish. Analyst ratings are opinions and do not guarantee future performance.

NeoGenomics, Inc. has a market capitalization of $2.15B. The company belongs to the Healthcare sector. Compare it with other companies in the stock screener.

In its most recent quarterly report, NeoGenomics, Inc. posted earnings of $0.07 per share against an estimate of $0.05546, beating expectations by 26.22%. Upcoming reports are listed in the earnings calendar.

NeoGenomics, Inc. reported revenue of $209.25M in its most recent quarter, which has increased by 11.43% compared with the same quarter a year earlier. Analysts had expected $206.7M.

Companies most comparable to NeoGenomics, Inc. include Guardant Health, Inc., GRAIL Inc., Veracyte, Inc., GeneDx Holdings Corp. and Personalis, Inc.

In the latest trading session NEO moved between $15.90 and $16.90, a range of 6.06% of its current price.

Investing in stocks requires thorough research: study the company's financials, related news and technical analysis before making a decision. Technical analysis of NeoGenomics, Inc. shows a sell rating today and a buy rating on the weekly timeframe. Market conditions change quickly, so it is worth looking further ahead as well — the 1-month rating for NeoGenomics, Inc. is buy. Technical ratings are indicators, not investment advice.

Over the past 52 weeks NEO has traded between $7.07 and $20.15. The current price is 18.06% below its 52-week high.